Literature DB >> 21975466

Gene therapy for retinal ganglion cell neuroprotection in glaucoma.

A M Wilson1, A Di Polo.   

Abstract

Glaucoma is the leading cause of irreversible blindness worldwide. The primary cause of glaucoma is not known, but several risk factors have been identified, including elevated intraocular pressure and age. Loss of vision in glaucoma is caused by the death of retinal ganglion cells (RGCs), the neurons that convey visual information from the retina to the brain. Therapeutic strategies aimed at delaying or halting RGC loss, known as neuroprotection, would be valuable to save vision in glaucoma. In this review, we discuss the significant progress that has been made in the use of gene therapy to understand mechanisms underlying RGC degeneration and to promote the survival of these neurons in experimental models of optic nerve injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975466     DOI: 10.1038/gt.2011.142

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

1.  Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

Authors:  R F Boyd; S L Boye; T J Conlon; K E Erger; D G Sledge; I M Langohr; W W Hauswirth; A M Komáromy; S E Boye; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2016-04-07       Impact factor: 5.250

Review 2.  Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Authors:  Morgan E Freret; David H Gutmann
Journal:  J Neurosci Res       Date:  2018-04-28       Impact factor: 4.164

Review 3.  Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

Authors:  Robert Listernick; Rosalie E Ferner; Grant T Liu; David H Gutmann
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

Review 4.  The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs.

Authors:  Teresa Borrás
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017 Jan-Feb

5.  Injectable Neurotrophic Factor Delivery System Supporting Retinal Ganglion Cell Survival and Regeneration Following Optic Nerve Crush.

Authors:  Melissa R Laughter; James R Bardill; David A Ammar; Brisa Pena; David J Calkins; Daewon Park
Journal:  ACS Biomater Sci Eng       Date:  2018-07-23

6.  Chimeric Helper-Dependent Adenoviruses Transduce Retinal Ganglion Cells and Müller Cells in Human Retinal Explants.

Authors:  Ian C Han; Erin R Burnight; Emily E Kaalberg; Timothy M Boyce; Edwin M Stone; John H Fingert; Robert F Mullins; Budd A Tucker; Luke A Wiley
Journal:  J Ocul Pharmacol Ther       Date:  2021-10-01       Impact factor: 2.671

7.  Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection.

Authors:  Nitin Chitranshi; Yogita Dheer; Mehdi Mirzaei; Yunqi Wu; Ghasem H Salekdeh; Mojdeh Abbasi; Veer Gupta; Roshana Vander Wall; Yuyi You; Stuart L Graham; Vivek Gupta
Journal:  Mol Ther       Date:  2018-10-04       Impact factor: 11.454

8.  Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma.

Authors:  Marius Chiasseu; Jorge L Cueva Vargas; Laurie Destroismaisons; Christine Vande Velde; Nicole Leclerc; Adriana Di Polo
Journal:  J Neurosci       Date:  2016-05-25       Impact factor: 6.167

Review 9.  Neuroprotection for glaucoma: Requirements for clinical translation.

Authors:  Leonard A Levin; Megan E Crowe; Harry A Quigley
Journal:  Exp Eye Res       Date:  2016-12-09       Impact factor: 3.467

10.  Surface Engineering of FLT4-Targeted Nanocarriers Enhances Cell-Softening Glaucoma Therapy.

Authors:  Michael P Vincent; Trevor Stack; Amir Vahabikashi; Guorong Li; Kristin M Perkumas; Ruiyi Ren; Haiyan Gong; W Daniel Stamer; Mark Johnson; Evan A Scott
Journal:  ACS Appl Mater Interfaces       Date:  2021-07-07       Impact factor: 10.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.